Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors
Advanced Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 84 (final count)
- Started
- Apr 19, 2021
- Main results expected
- Feb 22, 2024
- Fully finished
- Feb 22, 2024
- Results posted
- Mar 25, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)
Measured over: Up to 28 Days
Part 1: Recommended Phase 2 Dose (RP2D)
Measured over: Up to 28 Days
Objective Response Rate (ORR) as Assessed by the Investigator Based on Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1
Measured over: From date of randomization until the date of first documented progression or death from any cause, whichever came first (up to 2 years and 9 months)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04716634 · record last updated 2025-03-25 · checked 2026-11-09 15:42 UTC